Form 4: Heron Therapeutics, Inc. /De/ CEO Reports Stock Transaction
Insider Transaction (Form 4)
Craig A Collard, Chief Executive Officer and a Director of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.
Summary
- Option exercise/conversion: acquired 13,797 Common Stock on July 19, 2026; holds 771,682 after (Direct).
- Option exercise/conversion: disposed of 13,797 Restricted Stock Units on July 19, 2026; holds 82,781 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Craig A Collard — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-19 | Option exercise/conversion | Common Stock | 13,797 | — | — | 771,682 |
| 2026-07-19 | Option exercise/conversion | Restricted Stock Units | 13,797 | — | — | 82,781 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-19 | Option exercise/conversion (13,797 shares) |
| 2026-07-19 | Option exercise/conversion (13,797 shares) |
Keywords
insider transaction, Form 4, HRTX, HERON THERAPEUTICS, INC. /DE/, neutral, Craig A Collard
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.